Drugs / CD2475/101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01320033 | Mar 2011 → Jan 2012 | acne | Galderma R&D | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD2475/101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01320033 ↗ |
| Route | Oral | “Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.” NCT01320033 ↗ |